Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study
- PMID: 24798523
- DOI: 10.7326/M13-1879
Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study
Abstract
Background: Trials comparing implantable cardioverter-defibrillator (ICD) therapy with cardiac resynchronization therapy with a defibrillator (CRT-D) are limited to selected patients treated at centers with extensive experience.
Objective: To compare outcomes after CRT-D versus ICD therapy in contemporary practice.
Design: Retrospective cohort study using the National Cardiovascular Data Registry's ICD Registry linked with Medicare claims.
Setting: 780 U.S. hospitals implanting both CRT-D and ICD devices.
Patients: 7090 propensity-matched patients older than 65 years with reduced left ventricular ejection fraction (<0.35) and prolonged QRS duration on electrocardiography (≥120 ms) having CRT-D or ICD implantation between 1 April 2006 and 31 December 2009.
Measurements: Risks for death, readmission, and device-related complications over 3 years.
Results: Compared with ICD therapy, CRT-D was associated with lower risks for mortality (cumulative incidence, 25.7% vs. 29.8%; adjusted hazard ratio [HR], 0.82 [99% CI, 0.73 to 0.93]), all-cause readmission (cumulative incidence, 68.6% vs. 72.8%; adjusted HR, 0.86 [CI, 0.81 to 0.93]), cardiovascular readmission (cumulative incidence, 45.0% vs. 52.4%; adjusted HR, 0.80 [CI, 0.73 to 0.88]), and heart failure readmission (cumulative incidence, 24.3% vs. 29.4%; adjusted HR, 0.78 [CI, 0.69 to 0.88]). It was also associated with greater risks for device-related infection (cumulative incidence, 1.9% vs. 1.0%; adjusted HR, 1.90 [CI, 1.07 to 3.37]). The lower risks for heart failure readmission associated with CRT-D compared with ICD therapy were most pronounced among patients with left bundle branch block or a QRS duration at least 150 ms and in women.
Limitations: Patients were not randomly assigned to treatment groups, and few patients could be propensity-matched. The findings may not extend to younger patients or those outside of fee-for-service Medicare.
Conclusion: In older patients with reduced left ventricular ejection fraction and prolonged QRS duration, CRT-D was associated with lower risks for death and readmission than ICD therapy alone.
Primary funding source: Agency for Healthcare Research and Quality.
Similar articles
-
Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.Circ Heart Fail. 2016 Jun;9(6):10.1161/CIRCHEARTFAILURE.115.002324 e002324. doi: 10.1161/CIRCHEARTFAILURE.115.002324. Circ Heart Fail. 2016. PMID: 27296396 Free PMC article.
-
QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy.JAMA. 2013 Aug 14;310(6):617-26. doi: 10.1001/jama.2013.8641. JAMA. 2013. PMID: 23942680
-
Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block.J Am Heart Assoc. 2015 Jun 29;4(7):e002013. doi: 10.1161/JAHA.115.002013. J Am Heart Assoc. 2015. PMID: 26124205 Free PMC article. Clinical Trial.
-
Cardiac-resynchronization therapy in patients with systolic heart failure and QRS interval ≤130 ms: insights from a meta-analysis.Europace. 2015 Feb;17(2):267-73. doi: 10.1093/europace/euu214. Epub 2014 Aug 27. Europace. 2015. PMID: 25164431 Review.
-
Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis.Europace. 2012 Nov;14(11):1602-7. doi: 10.1093/europace/eus168. Europace. 2012. PMID: 23104857 Review.
Cited by
-
Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement.Heart Rhythm O2. 2021 Dec 17;2(6Part B):698-709. doi: 10.1016/j.hroo.2021.09.010. eCollection 2021 Dec. Heart Rhythm O2. 2021. PMID: 34988519 Free PMC article.
-
Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.JAMA Netw Open. 2021 Jan 4;4(1):e2035470. doi: 10.1001/jamanetworkopen.2020.35470. JAMA Netw Open. 2021. PMID: 33496796 Free PMC article.
-
Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults.Clin Cardiol. 2020 Feb;43(2):187-195. doi: 10.1002/clc.23315. Epub 2019 Dec 23. Clin Cardiol. 2020. PMID: 31867773 Free PMC article. Review.
-
Do We Need an Implantable Cardioverter-defibrillator for Primary Prevention in Cardiac Resynchronisation Therapy Patients?Arrhythm Electrophysiol Rev. 2018 Aug;7(3):157-158. doi: 10.15420/aer.2018.7.3.EO1. Arrhythm Electrophysiol Rev. 2018. PMID: 30416727 Free PMC article. Review. No abstract available.
-
Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator: Insights From the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.JAMA Cardiol. 2017 May 1;2(5):561-565. doi: 10.1001/jamacardio.2016.5388. JAMA Cardiol. 2017. PMID: 28122073 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous